癫痫孕妇后代2岁认知结局:MONEAD研究
MONEAD前瞻性多中心研究纳入292名癫痫孕妇后代和90名健康孕妇后代,在2岁时用BSID-III评估。主要语言域评分两组无差异(-0.5;95%CI -4.1至3.2),其他四域也无差异。但次要分析显示,孕晚期ASM最大血药浓度越高,运动域评分越低(-5.6;95%CI -10.7至-0.5);最大剂量越高,一般适应域评分越低(-1.4;95%CI -2.8至-0.05)。
要点
- 癫痫孕妇后代2岁时语言域评分与健康孕妇后代无差异。
- 孕晚期ASM最大血药浓度越高,后代运动域评分越低。
- 孕晚期ASM最大剂量越高,后代一般适应域评分越低。
核心结论
- 癫痫孕妇后代2岁时认知结局与健康孕妇后代无差异。
- 孕晚期ASM最大血药浓度和剂量与部分次要结局域评分呈负相关。
研究设计与样本
- MONEAD为前瞻性、观察性、多中心研究,2012年12月19日至2016年1月13日在美国20个癫痫中心入组孕妇。
- 共评估1123名孕妇,456名入组;最终分析292名癫痫孕妇后代和90名健康孕妇后代。
- 儿童从出生随访至6岁,本研究分析2岁时BSID-III评估数据。
主要发现
- 主要结局语言域评分两组无差异(-0.5;95%CI -4.1至3.2)。
- 其他4个BSID-III域(运动、认知、社会情绪、一般适应)两组均无差异。
- 癫痫孕妇后代中,ASM暴露与语言域无关联。
- 孕晚期最大ASM血药浓度越高,运动域评分越低(-5.6;95%CI -10.7至-0.5)。
- 孕晚期最大ASM剂量越高,一般适应域评分越低(-1.4;95%CI -2.8至-0.05)。
关键数值与推荐
- 主要结局为BSID-III语言域评分。
- BSID-III包含语言、运动、认知、社会情绪和一般适应5个域评分。
- 多数癫痫孕妇使用拉莫三嗪和/或左乙拉西坦。
临床怎么用
- 癫痫孕妇后代2岁认知结局与健康孕妇后代无显著差异,提供 reassuring 证据。
- 孕晚期ASM血药浓度和剂量监测可能有助于评估后代运动及适应能力风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The neurodevelopmental risks of fetal exposure are uncertain for many antiseizure medications (ASMs). OBJECTIVE: To compare children at 2 years of age who were born to women with epilepsy (WWE) vs healthy women and assess the association of maximum ASM exposure in the third trimester and subsequent cognitive abilities among children of WWE. DESIGN, SETTING, AND PARTICIPANTS: The Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) study is a prospective, observational, multicenter investigation of pregnancy outcomes that enrolled women from December 19, 2012, to January 13, 2016, at 20 US epilepsy centers. Children are followed up from birth to 6 years of age, with assessment at 2 years of age for this study. Of 1123 pregnant women assessed, 456 were enrolled; 426 did not meet criteria, and 241 chose not to participate. Data were analyzed from February 20 to December 4, 2020. MAIN OUTCOMES AND MEASURES: Language domain score according to the Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III), which incorporates 5 domain scores (language, motor, cognitive, social-emotional, and general adaptive), and association between BSID-III language domain and ASM blood levels in the third trimester in children of WWE. Analyses were adjusted for multiple potential confounding factors, and measures of ASM exposure were assessed. RESULTS: The BSID-III assessments were analyzed in 292 children of WWE (median age, 2.1 [range, 1.9-2.5] years; 155 female [53.1%] and 137 male [46.9%]) and 90 children of healthy women (median age, 2.1 [range, 2.0-2.4] years; 43 female [47.8%] and 47 male [52.2%]). No differences were found between groups on the primary outcome of language domain (-0.5; 95% CI, -4.1 to 3.2). None of the other 4 BSID-III domains differed between children of WWE vs healthy women. Most WWE were taking lamotrigine and/or levetiracetam. Exposure to ASMs in children of WWE showed no association with the language domain. However, secondary analyses revealed that higher maximum observed ASM levels in the third trimester were associated with lower BSID-III scores for the motor domain (-5.6; 95% CI, -10.7 to -0.5), and higher maximum ASM doses in the third trimester were associated with lower scores in the general adaptive domain (-1.4; 95% CI, -2.8 to -0.05). CONCLUSIONS AND RELEVANCE: Outcomes of children at 2 years of age did not differ between children of WWE taking ASMs and children of healthy women. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01730170.
引用
- Meador KJ, Cohen MJ, Loring DW, et al. Two-Year-Old Cognitive Outcomes in Children of Pregnant Women With Epilepsy in the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs Study. JAMA Neurol. 2021. PMID: 34096986. doi:10.1001/jamaneurol.2021.1583
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。